João Ribas

Partner at Novo Holdings · Joined 2018

View Live Interactive Profile →

Biography

João Ribas joined Novo Holdings Seed Investments in 2018, focusing on early-stage investments and venture creation, and is listed on the firm's people page as a Partner. Novo Holdings says he holds several board positions and has led investments in Asgard Therapeutics, Tribune Therapeutics and Orbis Medicines, and that he often combines his investment role with interim operational responsibilities in portfolio companies. Before Novo Holdings he was a Fellow at M Ventures, the corporate venture capital arm of Merck KGaA, and earlier founded new ventures in the United States and Europe. He earned his PhD from the University of Coimbra, conducting research at Harvard Medical School and Brigham and Women's Hospital. Novo Holdings press releases in January and March 2025 describe him as Principal rather than Partner.

Education

Previous Experience

Notable Investments

Orbis MedicinesTribune Therapeutics

Career Timeline

2018
Joins Novo Holdings Seed Investments, focusing on early-stage investments and venture creation.
2025
Quoted as Principal, Novo Holdings in the announcements of Orbis Medicines' EUR 90 million Series A and Tribune Therapeutics' EUR 23 million Series A.

Sources & References

Novo Holdings - João Ribas (people page, checked 6 September 2026) ↗Novo Holdings participates in EUR 90 million Series A for Orbis Medicines (6 January 2025) ↗Novo Holdings participates in EUR 23 million Series A for Tribune Therapeutics (26 March 2025) ↗